Department of Veterans Affairs

§4.104

	Rating
General Rating Formula for Restrictive Lung Disease (diagnostic codes 6840 through 6845): FEV-1 less than 40 percent of predicted value, or; the ratio of Forced Expiratory Volume in one second to Forced Vital Capacity (FEV-1/FVC) less than 40 percent, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption (with cardiac or respiratory limitation), or; cor pulmonale (right heart failure), or; right ventricular hypertrophy, or; pulmonary hypertension (shown by Echo or cardiac catheterization), or; episode(s) of acute respiratory failure, or; requires outpatient oxygen therapy FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; DLCO (SB) of 40- to 55-percent predicted, or; maximum oxygen consumption of 15 to 20 ml/kg/min (with cardiorespiratory limit)	100 60 30
FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of 71 to 80 percent, or; DLCO (SB) 66- to 80-percent predicted	10
Or rate primary disorder. Note (1): A 100-percent rating shall be assigned for pleurisy with empyema, with or without pleurocutaneous fistula, until resolved.	
Note (2): Following episodes of total spontaneous pneumothorax, a rating of 100 percent shall be assigned as of the date of hospital admission and shall continue for three months from the first day of the month after hospital discharge.	
Note (3): Gunshot wounds of the pleural cavity with bullet or missile retained in lung, pain or discomfort on exertion, or with scattered rales or some limitation of excursion of diaphragm or of lower chest expansion shall be rated at least 20-percent disabling. Disabling injuries of shoulder girdle muscles (Groups I to IV) shall be separately rated and combined with ratings for respiratory involvement. Involvement of Muscle Group XXI (DC 5321), however, will not be separately rated.	
6846 Sarcoidosis: Cor pulmonale, or; cardiac involvement with congestive heart failure, or; progressive pulmonary disease with fever, night sweats, and weight loss despite treatment Pulmonary involvement requiring systemic high dose (therapeutic) corticosteroids for control Pulmonary involvement with persistent symptoms requiring chronic low dose (maintenance) or intermittent corticosteroids	100 60 30
Chronic hilar adenopathy or stable lung infiltrates without symptoms or physiologic impairment	0
6847 Sleep Apnea Syndromes (Obstructive, Central, Mixed): Chronic respiratory failure with carbon dioxide retention or cor pulmonale, or; requires tracheostomy Requires use of breathing assistance device such as continuous airway pressure (CPAP) machine Persistent day-time hypersomnolence Asymptomatic but with documented sleep disorder breathing	100 50 30 0

¹ Review for entitlement to special monthly compensation under §3.350 of this chapter.

[61 FR 46728, Sept. 5, 1996]

THE CARDIOVASCULAR SYSTEM

§§ 4.100-4.103 [Reserved]

§4.104 Schedule of ratings—cardiovascular system.

DISEASES OF THE HEART

		Rat- ing
NOTE (1): Evaluate cor pulmonale, which is a form	m of	

NOTE (1): Evaluate cor pulmonale, which is a form of secondary heart disease, as part of the pulmonary condition that causes it.

	Rat- ing
NOTE (2): One MET (metabolic equivalent) is the energy cost of standing quietly at rest and represents an oxygen uptake of 3.5 milliliters per kilogram of body weight per minute. When the level of METs at which dyspnea, fatigue, angina, dizziness, or syncope develops is required for evaluation, and a laboratory determination of METs by exercise testing cannot be done for medical reasons, an estimation by a medical examiner of the level of activity (expressed in METs and supported by specific examples, such as slow stair climbing or shoveling snow) that results in dyspnea, fatigue, angina, dizziness, or syncope may be used.	
heart disease):	
During active infection with valvular heart damage and for three months following cessation of therapy for the active infec-	

38 CFR Ch. I (7-1-01 Edition)

DISEASES OF THE HEART—Continued

DISEASES OF THE HEART—Continued

		Rat- ing	Rat- ing
	Thereafter, with valvular heart disease (doc- umented by findings on physical examina- tion and either echocardiogram, Doppler echocardiogram, or cardiac catheteriza- tion) resulting in:		More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven-
	Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent	100	tricular dysfunction with an ejection frac- tion of 30 to 50 percent
	More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven-		evidence of cardiac hypertrophy or dilatation on electro-cardiogram, echocardiogram, or X-ray
	tricular dysfunction with an ejection fraction of 30 to 50 percent	60	fatigue, angina, dizziness, or syncope, or; continuous medication required
	Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or, evidence of cardiac hypertrophy or dilatation on electro-cardiogram, echocardiogram, or X-ray	30	7003 Pericardial adhesions: Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent
7004	Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required	10	More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue,
7001	Endocarditis: For three months following cessation of therapy for active infection with cardiac involvement	100	angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac- tion of 30 to 50 percent
	Thereafter, with endocarditis (documented by findings on physical examination and either echocardiogram, Doppler echo- cardiogram, or cardiac catheterization) re-		greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata- tion on electro-cardiogram, echocardio-
	sulting in: Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or;		gram, or X-ray
	left ventricular dysfunction with an ejection fraction of less than 30 percent	100	continuous medication required
	angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac- tion of 30 to 50 percent	60	fraction of less than 30 percent
	evidence of cardiac hypertrophy or dilata- tion on electrocardiogram, echocardio- gram, or X-ray	30	tricular dysfunction with an ejection frac- tion of 30 to 50 percent
7002	fatigue, angina, dizziness, or syncope, or; continuous medication required Pericarditis: For three months following cessation of	10	evidence of cardiac hypertrophy or dilata- tion on electrocardiogram, echocardio- gram, or X-ray
	therapy for active infection with cardiac in- volvement	100	greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required
	sulting in: Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent.	100	Note: Evaluate syphilitic aortic aneurysms under DC 7110 (aortic aneurysm).

Department of Veterans Affairs

§4.104

DISEASES OF THE HEART—Continued

	Rat- ing			Rat- ing
7005 Arteriosclerotic heart disease (Coronary artery disease): With documented coronary artery disease resulting in:			More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven-	
Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection			tricular dysfunction with an ejection fraction of 30 to 50 percent	60
fraction of less than 30 percent	100		greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata- tion on electrocardiogram, echocardio-	
than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac-			gram, or X-ray Workload of greater than 7 METs but not greater than 10 METs results in dyspnea,	30
tion of 30 to 50 percent Workload of greater than 5 METs but not greater than 7 METs results in dyspnea,	60	7008	fatigue, angina, dizziness, or syncope, or; continuous medication required	10
fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata- tion on electrocardiogram, echocardio- gram, or X-ray	30		Include as part of the overall evaluation for hyperthyroidism under DC 7900. However, when atrial fibrillation is present, hyperthyroidism may be evaluated either	
Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or;			under DC 7900 or under DC 7010 (supraventricular arrhythmia), whichever results in a higher evaluation.	
continuous medication required NOTE: If nonservice-connected arteriosclerotic heart disease is superimposed on service-connected val-	10	7010	Supraventricular arrhythmias: Paroxysmal atrial fibrillation or other supra- ventricular tachycardia, with more than	
vular or other non-arteriosclerotic heart disease, request a medical opinion as to which condition is causing the current signs and symptoms.			four episodes per year documented by ECG or Holter monitor	30
7006 Myocardial infarction: During and for three months following myo- cardial infarction, documented by labora-			of paroxysmal atrial fibrillation or other su- praventricular tachycardia documented by ECG or Holter monitor	10
tory tests	100	7011	Ventricular arrhythmias (sustained): For indefinite period from date of hospital admission for initial evaluation and med- ical therapy for a sustained ventricular ar-	
farction, resulting in: Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea,			rhythmia, or; for indefinite period from date of hospital admission for ventricular aneurysmectomy, or; with an automatic	
fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent	100		implantable Cardioverter-Defibrillator (AICD) in place	100
More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater			load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection	
than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection frac-			fraction of less than 30 percent	100
tion of 30 to 50 percent	60		of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac-	
evidence of cardiac hypertrophy or dilata- tion on electrocardiogram, echocardio- gram, or X-ray	30		tion of 30 to 50 percent	60
greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required	10		evidence of cardiac hypertrophy or dilata- tion on electrocardiogram, echocardio- gram, or X-ray	30
7007 Hypertensive heart disease: Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or;			Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or;	
left ventricular dysfunction with an ejection fraction of less than 30 percent	100		continuous medication required	l 10

38 CFR Ch. I (7-1-01 Edition)

DISEASES OF THE HEART—Continued

	Rat- ing		Rat- ing
NOTE: A rating of 100 percent shall be assigned from the date of hospital admission for initial evaluation and medical therapy for a sustained ventricular arrhythmia or for ventricular aneurysmectomy. Six months following discharge, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter.		Note: A rating of 100 percent shall be assigned as of the date of hospital admission for valve replacement. Six months following discharge, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. 7017 Coronary bypass surgery: For three months following hospital admis-	
7015 Atrioventricular block: Chronic congestive heart failure, or; work-load of 3 METs or less results in dyspnea,		sion for surgery Thereafter: Chronic congestive heart failure, or; work-load of 3 METs or less results in dyspnea,	100
fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent	100	fatigue, angina, dizziness, or syncope, or, left ventricular dysfunction with an ejection fraction of less than 30 percent	100
than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac-		than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection frac-	
tion of 30 to 50 percent	60	tion of 30 to 50 percent	60
tion on electrocardiogram, echocardio- gram, or X-ray	30	gram, or X-ray Workload greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or,	30
continuous medication or a pacemaker required	10	continuous medication required	10
NOTE: Unusual cases of arrhythmia such as atrio- ventricular block associated with a supraventricular arrhythmia or pathological bradycardia should be submitted to the Director, Compensation and Pen- sion Service. Simple delayed P–R conduction time, in the absence of other evidence of cardiac dis-		for implantation or reimplantation	100
ease, is not a disability. 7016 Heart valve replacement (prosthesis):		NOTE: Evaluate implantable Cardioverter-Defibrillators (AICD's) under DC 7011.	
For indefinite period following date of hospital admission for valve replacement Thereafter: Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea,	100	7019 Cardiac transplantation: For an indefinite period from date of hospital admission for cardiac transplantation Thereafter: Chronic congestive heart failure, or; work-	100
fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent	100	load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent	100
heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection frac-		More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven-	
tion of 30 to 50 percent	60	tricular dysfunction with an ejection frac- tion of 30 to 50 percent	60 30
fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata- tion on electrocardiogram, echocardio- gram, or X-ray	30	NOTE: A rating of 100 percent shall be assigned as of the date of hospital admission for cardiac trans- plantation. One year following discharge, the ap- propriate disability rating shall be determined by mandatory VA examination. Any change in evalua- tion based upon that or any subsequent examina-	
fatigue, angina, dizziness, or syncope, or; continuous medication required	10	tion shall be subject to the provisions of §3.105(e) of this chapter.	

Department of Veterans Affairs

§4.104

DISEASES OF THE HEART—Continued

	Rat- ing		Rat-
Cardiomyopathy: Chronic congestive heart failure, or; work-load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent	100 60 30 10 60 40 20	If symptomatic, or; for indefinite period from date of hospital admission for surgical correction	100 100 60 40 20
NOTE (1): Hypertension or isolated systolic hypertension must be confirmed by readings taken two or more times on at least three different days. For purposes of this section, the term hypertension means that the diastolic blood pressure is predominantly 90mm. or greater, and isolated systolic hypertension means that the systolic blood pressure is predominantly 160mm. or greater with a diastolic blood pressure of less than 90mm. NOTE (2): Evaluate hypertension due to aortic insufficiency or hyperthyroidism, which is usually the isolated systolic type, as part of the condition causing it rather than by a separate evaluation. 7110 Aortic aneurysm: If five centimeters or larger in diameter, or; if symptomatic, or; for indefinite period from date of hospital admission for surgical correction (including any type of graft insertion) Precluding exertion Evaluate residuals of surgical correction according to organ systems affected. NOTE: A rating of 100 percent shall be assigned as of the date of admission for surgical correction. Six months following discharge, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter.	100 60	7112 Aneurysm, any small artery: Asymptomatic	100 60 50 40 30 20

38 CFR Ch. I (7-1-01 Edition)

	Rat-		Rat- ing
Claudication on walking more than 100 yards, and; diminished peripheral pulses or ankle/brachial index of 0.9 or less NOTE (1): The ankle/brachial index is the ratio of the exterior blood presument the parkle (determined by	20	Attacks without laryngeal involvement lasting one to seven days and occurring five to eight times a year, or; attacks with laryngeal involvement of any duration occurring once or twice a year	20
systolic blood pressure at the ankle (determined by Doppler study) divided by the simultaneous brach- ial artery systolic blood pressure. The normal index is 1.0 or greater.		Attacks without laryngeal involvement lasting one to seven days and occurring two to four times a year	10
NOTE (2): Evaluate residuals of aortic and large arte- rial bypass surgery or arterial graft as arterio- sclerosis obliterans. NOTE (3): These evaluations are for involvement of a single extremity. If more than one extremity is af- fected, evaluate each extremity separately and		7119 Erythromelalgia: Characteristic attacks that occur more than once a day, last an average of more than two hours each, respond poorly to treatment, and that restrict most routine daily activities	100
combine (under §4.25), using the bilateral factor (§4.26), if applicable. 7115 Thrombo-angiitis obliterans (Buerger's Dis-		Characteristic attacks that occur more than once a day, last an average of more than two hours each, and respond poorly to	
ease): Ischemic limb pain at rest, and; either deep ischemic ulcers or ankle/brachial index of		treatment, but that do not restrict most routine daily activities	60
0.4 or less	100	more often but that respond to treatment Characteristic attacks that occur less than daily but at least three times a week and	30
either persistent coldness of the extremity or ankle/brachial index of 0.5 or less Claudication on walking between 25 and 100 yards on a level grade at 2 miles per hour, and; trophic changes (thin skin, ab-	60	that respond to treatment	10
sence of hair, dystrophic nails) or ankle/ brachial index of 0.7 or less	40	redness, occurring at warm ambient temperatures. These evaluations are for the disease as a whole, regardless of the number of extremities involved.	
or ankle/brachial index of 0.9 or less NOTE (1): The ankle/brachial index is the ratio of the systolic blood pressure at the ankle (determined by Doppler study) divided by the simultaneous brachial artery systolic blood pressure. The normal index is 1.0 or greater. NOTE (2): These evaluations are for involvement of a single extremity. If more than one extremity is affected, evaluate each extremity separately and combine (under § 4.25), using the bilateral factor (§ 4.26), if applicable.	20	7120 Varicose veins: With the following findings attributed to the effects of varicose veins: Massive board-like edema with constant pain at rest Persistent edema or subcutaneous induration, stasis pigmentation or eczema, and persistent ulceration Persistent edema and stasis pigmentation or eczema, with or without intermittent ulceration Persistent edema, incompletely relieved by elevation of extremity, with or without be-	100 60 40 20
With two or more digital ulcers plus autoamputation of one or more digits and history of characteristic attacks	100 60	ginning stasis pigmentation or eczema Intermittent edema of extremity or aching and fatigue in leg after prolonged standing or walking, with symptoms relieved by elevation of extremity or compression hosiery	10
daily	40 20 10	veins	0
digits of one or more extremities lasting minutes to hours, sometimes with pain and paresthesias, and precipitated by exposure to cold or by emotional upsets. These evaluations are for the disease as a whole, regardless of the number of extremities involved or whether the nose and ears are involved.		7121 Post-phlebitic syndrome of any etiology: With the following findings attributed to venous disease: Massive board-like edema with constant pain at rest Persistent edema or subcutaneous	100
7118 Angioneurotic edema: Attacks without laryngeal involvement lasting one to seven days or longer and occurring more than eight times a year, or;		induration, stasis pigmentation or eczema, and persistent ulceration Persistent edema and stasis pig-	60
attacks with laryngeal involvement of any duration occurring more than twice a year	40	mentation or eczema, with or without intermittent ulceration	40

DISEASES OF THE HEART—Continued

NOTE: These evaluations are for involvement of a single extremity. If more than one extremity is involved, evaluate each extremity separately and combine (under §4.25), using the bilateral factor (§4.26), if applicable.

7122 Cold injury residuals:

With the following in affected parts:

Arthralgia or other pain, numbness, or cold sensitivity plus two or more of the following: tissue loss, nail abnormalities, color changes, locally impaired sensation, hyperhidrosis, X-ray abnormalities (osteoporosis, subarticular punched out lesions, or osteo-arthritis)

Arthralgia or other pain, numbness, or cold sensitivity plus tissue loss, nail abnormalities, color changes, locally impaired sensation, hyperhidrosis, or X-ray abnormalities (osteoporosis, subarticular punched out lesions, or osteoarthritis)

Arthralgia or other pain, numbness, or cold sensitivity

NOTE (1): Separately evaluate amputations of fingers or toes, and complications such as squamous cell carcinoma at the site of a cold injury scar or peripheral neuropathy, under other diagnostic codes. Separately evaluate other disabilities that have been diagnosed as the residual effects of cold injury, such as Raynaud's phenomenon, muscle atrophy, etc., unless they are used to support an evaluation under diagnostic code 7122.

NOTE (2): Evaluate each affected part (e.g., hand, foot, ear, nose) separately and combine the ratings in accordance with §§ 4.25 and 4.26.

7123 Soft tissue sarcoma (of vascular origin)

NOTE: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.

(Authority: 38 U.S.C. 1155)

[62 FR 65219, Dec. 11, 1997, as amended at 63 FR 37779, July 14, 1998]

THE DIGESTIVE SYSTEM

§4.110 Ulcers.

Rat-

ing

Experience has shown that the term "peptic ulcer" is not sufficiently specific for rating purposes. Manifest differences in ulcers of the stomach or duodenum in comparison with those at an anastomotic stoma are sufficiently recognized as to warrant two separate graduated descriptions. In evaluating the ulcer, care should be taken that the findings adequately identify the particular location.

§4.111 Postgastrectomy syndromes.

There are various postgastrectomy symptoms which may occur following anastomotic operations of the stomach. When present, those occurring during or immediately after eating and known as the "dumping syndrome" are characterized by gastrointestinal complaints and generalized symptoms simulating hypoglycemia; those occurring from 1 to 3 hours after eating usually present definite manifestations of hypoglycemia.

§4.112 Weight loss.

Minor weight loss or greater losses of weight for periods of brief duration are not considered of importance in rating. Rather, weight loss becomes of importance where there is appreciable loss which is sustained over a period of time. In evaluating weight loss generally, consideration will be given not only to standard age, height, and weight tables, but also to the parpredominant individual's weight pattern as reflected by the records. The use of the term "inability to gain weight" indicates that there has been a significant weight loss with inability to regain it despite appropriate therapy.

EFFECTIVE DATE NOTE: At 66 FR 29488, May 31, 2001, §4.112 was revised, effective July 2, 2001. For the convenience of the user, the revised text is set forth as follows:

§ 4.112 Weight loss.

For purposes of evaluating conditions in §4.114, the term "substantial weight loss" means a loss of greater than 20 percent of the individual's baseline weight, sustained for three months or longer; and the term "minor weight loss" means a weight loss of 10 to 20 percent of the individual's baseline weight,